Depleting hepatitis B virus relaxed circular DNA is necessary for resolution of infection by CRISPR-Cas9

[1]  Yujie Sun,et al.  Digital Counting of Breaks Labeling In Situ: A Fast and Absolute Quantification Method for Measurement of DNA Double-Strand Breaks Based on Digital Polymerase Chain Reaction. , 2022, Analytical chemistry.

[2]  P. Mangeot,et al.  CRISPR-Cas9 Targeting of Hepatitis B Virus Covalently Closed Circular DNA Generates Transcriptionally Active Episomal Variants , 2022, mBio.

[3]  A. Kostyusheva,et al.  CRISPR/Cas and Hepatitis B Therapy: Technological Advances and Practical Barriers. , 2021, Nucleic acid therapeutics.

[4]  T. Volz,et al.  Therapeutic shutdown of HBV transcripts promotes reappearance of the SMC5/6 complex and silencing of the viral genome in vivo , 2021, Gut.

[5]  Huimin Zhao,et al.  TALEN outperforms Cas9 in editing heterochromatin target sites , 2021, Nature Communications.

[6]  Jiming Zhang,et al.  Restoration of a functional antiviral immune response to chronic HBV infection by reducing viral antigen load: if not sufficient, is it necessary? , 2021, Emerging microbes & infections.

[7]  Hong Li,et al.  The molecular basis for recognition of 5′-NNNCC-3′ PAM and its methylation state by Acidothermus cellulolyticus Cas9 , 2020, Nature Communications.

[8]  K. Agarwal,et al.  The Role of RNA Interference in Functional Cure Strategies for Chronic Hepatitis B , 2020, Current Hepatology Reports.

[9]  A. Lukashev,et al.  Gene Editing by Extracellular Vesicles , 2020, International journal of molecular sciences.

[10]  Katie Weiner.  Impact of chromatin context on Cas9-induced DNA double-strand break repair pathway balance , 2020 .

[11]  R. Medema,et al.  Impact of chromatin context on Cas9-induced DNA double-strand break repair pathway balance , 2020, bioRxiv.

[12]  Ciaran M. Lee,et al.  AAV-CRISPR Gene Editing Is Negated by Pre-existing Immunity to Cas9 , 2020, Molecular therapy : the journal of the American Society of Gene Therapy.

[13]  M. Manns,et al.  RNA Interference Therapy With ARC‐520 Results in Prolonged Hepatitis B Surface Antigen Response in Patients With Chronic Hepatitis B Infection , 2020, Hepatology.

[14]  Hui Yang,et al.  Allele-specific genome editing of imprinting genes by preferentially targeting non-methylated loci using Staphylococcus aureus Cas9 (SaCas9). , 2019, Science bulletin.

[15]  Joan M. Block,et al.  A global scientific strategy to cure hepatitis B. , 2019, The lancet. Gastroenterology & hepatology.

[16]  G. Cullot,et al.  CRISPR-Cas9 genome editing induces megabase-scale chromosomal truncations , 2019, Nature Communications.

[17]  A. Kostyusheva,et al.  Suppressing the NHEJ pathway by DNA-PKcs inhibitor NU7026 prevents degradation of HBV cccDNA cleaved by CRISPR/Cas9 , 2019, Scientific Reports.

[18]  A. Kostyusheva,et al.  Orthologous CRISPR/Cas9 systems for specific and efficient degradation of covalently closed circular DNA of hepatitis B virus , 2019, Cellular and Molecular Life Sciences.

[19]  Tracy J. Ballinger,et al.  Heterochromatin delays CRISPR-Cas9 mutagenesis but does not influence the outcome of mutagenic DNA repair , 2018, PLoS biology.

[20]  J. McKeating,et al.  Hepatitis B virus genome recycling and de novo secondary infection events maintain stable cccDNA levels. , 2018, Journal of hepatology.

[21]  Waseem Akhtar,et al.  Kinetics and Fidelity of the Repair of Cas9-Induced Double-Strand DNA Breaks , 2018, Molecular cell.

[22]  Zhanhui Wang,et al.  Inhibition of hepatitis B virus replication via HBV DNA cleavage by Cas9 from Staphylococcus aureus , 2018, Antiviral research.

[23]  Jin-Soo Kim,et al.  Genome surgery using Cas9 ribonucleoproteins for the treatment of age-related macular degeneration. , 2017, Genome research.

[24]  V. Myer,et al.  Characterization of the interplay between DNA repair and CRISPR/Cas9-induced DNA lesions at an endogenous locus , 2017, Nature Communications.

[25]  Wei Zhu,et al.  CRISPR/Cas9 produces anti-hepatitis B virus effect in hepatoma cells and transgenic mouse. , 2016, Virus research.

[26]  C. Seeger,et al.  Complete Spectrum of CRISPR/Cas9-induced Mutations on HBV cccDNA , 2016, Molecular therapy : the journal of the American Society of Gene Therapy.

[27]  Boping Zhou,et al.  The recombined cccDNA produced using minicircle technology mimicked HBV genome in structure and function closely , 2016, Scientific Reports.

[28]  M. Jasin,et al.  Distinct genetic control of homologous recombination repair of Cas9-induced double-strand breaks, nicks and paired nicks , 2016, Nucleic acids research.

[29]  Liang Li,et al.  Large genomic fragment deletion and functional gene cassette knock-in via Cas9 protein mediated genome editing in one-cell rodent embryos , 2015, Scientific Reports.

[30]  Xiao-Hui Zhang,et al.  Off-target Effects in CRISPR/Cas9-mediated Genome Engineering , 2015, Molecular therapy. Nucleic acids.

[31]  Meghan M. Holdorf,et al.  Mapping of histone modifications in episomal HBV cccDNA uncovers an unusual chromatin organization amenable to epigenetic manipulation , 2015, Proceedings of the National Academy of Sciences.

[32]  Xiangmei Chen,et al.  Dual gRNAs guided CRISPR/Cas9 system inhibits hepatitis B virus replication. , 2015, World journal of gastroenterology.

[33]  Yu Chen,et al.  Inhibition of hepatitis B virus by the CRISPR/Cas9 system via targeting the conserved regions of the viral genome. , 2015, The Journal of general virology.

[34]  David A. Scott,et al.  CRISPR/Cas9 cleavage of viral DNA efficiently suppresses hepatitis B virus , 2015, Scientific Reports.

[35]  Surbhi Jain,et al.  Comprehensive DNA methylation analysis of hepatitis B virus genome in infected liver tissues , 2015, Scientific Reports.

[36]  J. Fu,et al.  Harnessing the clustered regularly interspaced short palindromic repeat (CRISPR)/CRISPR-associated Cas9 system to disrupt the hepatitis B virus , 2015, Gene Therapy.

[37]  B. Cullen,et al.  Suppression of hepatitis B virus DNA accumulation in chronically infected cells using a bacterial CRISPR/Cas RNA-guided DNA endonuclease. , 2015, Virology.

[38]  David A. Scott,et al.  CRISPR / Cas 9 cleavage of viral DNA efficiently suppresses hepatitis B virus , 2015 .

[39]  C. Seeger,et al.  Targeting Hepatitis B Virus With CRISPR/Cas9 , 2014, Molecular therapy. Nucleic acids.

[40]  Sheng-Nan Lu,et al.  The role of hepatitis B surface antigen quantification in predicting HBsAg loss and HBV relapse after discontinuation of lamivudine treatment. , 2014, Journal of hepatology.

[41]  Ding-Shinn Chen,et al.  The CRISPR/Cas9 System Facilitates Clearance of the Intrahepatic HBV Templates In Vivo , 2014, Molecular therapy. Nucleic acids.

[42]  Daesik Kim,et al.  Highly efficient RNA-guided genome editing in human cells via delivery of purified Cas9 ribonucleoproteins , 2014, Genome research.

[43]  T. Liang,et al.  Specific and Nonhepatotoxic Degradation of Nuclear Hepatitis B Virus cccDNA , 2014, Science.

[44]  James E. DiCarlo,et al.  RNA-Guided Human Genome Engineering via Cas9 , 2013, Science.

[45]  T. Block,et al.  A southern blot assay for detection of hepatitis B virus covalently closed circular DNA from cell cultures. , 2013, Methods in molecular biology.

[46]  F. Rodríguez-Frías,et al.  [Molecular virology of the hepatitis B virus]. , 2008, Enfermedades infecciosas y microbiologia clinica.

[47]  C. Gibbs,et al.  Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy. , 2004, Gastroenterology.